San Diego, California
April 17-22, 2026
Booth: 1423
Connect with Caris Life Sciences at AACR 2026
Caris Life Sciences® is proud to join the AACR Annual Meeting in San Diego, Califronia. Meet our team at booth #1423 to discover the latest innovations in precision medicine and learn how our products and services are leading the molecular revolution.
Caris Abstracts and Poster Schedule
Caris’ strong presence at the AACR 2026 demonstrates the clinical value of comprehensive molecular profiling and our commitment to transforming lives through research. Download the abstracts and presentation schedule, including a full list of summaries highlighting the research presented during AACR 2026.
Poster Presentations
1200/1: Spatially resolved tumor-cell MHC class II shapes adaptive immunity and therapeutic response in triplenegative breast cancer.
Presenter: Saranya Chumsri
Session: PO.CL01.12 – Spatial Proteomics and Transcriptomics 1
Time: 2:00 PM – 5:00 PM PST
Date: Sunday, April 19, 2026
Location: Poster Section 47
2434/4: Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET-rearranged advanced NSCLC.
Presenter: Daniela Miliziano
Session: PO.CL01.03 – Biomarkers Predictive of Therapeutic Benefit 3
Time: 9:00 AM – 12:00 PM PST
Date: Monday, April 20, 2026
Location: Poster Section 40
View the full schedule and more in the complete abstract booklet.
Schedule a Meeting
Products At-a-Glance
Caris Assure
Whole Exome and Whole Transcriptome Sequencing from blood. This revolutionary, pan-cancer assay utilizes a novel circulating Nucleic Acid Sequencing (cNAS) approach. With deep molecular insights from a minimally invasive blood sample, Caris Assure™ delivers uncompromising reliability and performance to inform personalized treatment decisions to help improve patient outcomes.
MI Cancer Seek
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.
Caris Molecular AI
With one of the largest, multi-modal databases of combined molecular and clinical outcomes data in the world, Caris applies highly sophisticated AI bioinformatics and machine learning capabilities on this massive database to create novel, clinically relevant solutions to classify cancer at the molecular level and predict patient response in ways never before possible.
Complete Molecular Intelligence Report
The Caris Molecular Profiling Report delivers high impact results, including potentially relevant, actionable clinical information, in an easy-to-interpret format. Every report includes access to the MI Portal and the Clinical Trials Connector™, which matches each patient’s unique biomarker expression profile to open, pertinent clinical trial opportunities.
Discover
More
Personalized Treatment Starts Here
Understanding cancer at the molecular level can lead to better treatment options. Caris molecular profiling includes whole exome and whole transcriptome sequencing of tissue and blood, plus protein analysis and other testing options for tissue specimens. Paired with molecular AI tools, Caris comprehensive molecular profiling is focused on helping cancer patients today and tomorrow.
Expert Scientific and Clinical Support
Caris’ healthcare provider services help put precision medicine into practice. Deep molecular insights enable physicians to navigate among therapies with potential benefit, identify therapies that may not have been considered, determine drugs unlikely to provide benefit (avoiding unnecessary toxicities and costs) and match patients to clinical trials.